AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972, TO INCLUDE FIVE SUBSTANCES AS SCHEDULE I CONTROLLED SUBSTANCES BECAUSE THESE DRUGS HAVE NO LEGITIMATE MEDICAL USE AND HAVE A HIGH POTENCY WITH GREAT POTENTIAL TO CAUSE HARM; AND FOR RELATED PURPOSES.
HB417 amends Mississippi’s Uniform Controlled Substances Act, specifically Section 41-29-113, to add five substances to Schedule I. The bill’s stated purpose is to classify these drugs as having no legitimate medical use and a high potential for harm. In practice, the measure updates the state’s controlled-substance list to capture additional synthetic drugs and related compounds, including emerging fentanyl-type substances and other high-risk analogs.
The bill is primarily a technical but consequential drug-control update. By placing the listed substances in Schedule I, it makes their manufacture, possession, distribution, and related conduct subject to Mississippi’s most restrictive controlled-substance penalties, unless an exemption or separate authorization applies. The bill also preserves and clarifies existing exemptions for hemp, FDA-approved cannabidiol products, and certain industrial or non-consumable hemp-derived products, while maintaining broad coverage over fentanyl-related substances, synthetic cannabinoids, synthetic cathinones, depressants, stimulants, and other hallucinogens already listed in the statute. The act takes effect July 1, 2026.
The overall sentiment appears strongly supportive and noncontroversial. The House passed the bill 118-0, and the Senate later passed it 52-0 as amended, indicating unanimous support in both chambers. The lack of committee transcript material also suggests there was little recorded public dispute or extended debate around the measure.
Any contention is likely limited to the breadth of the scheduling language rather than the concept of drug control itself. The bill uses expansive chemical-family definitions, especially for fentanyl-related substances, synthetic cannabinoids, and synthetic cathinones, which can raise concerns about overbreadth, future-proofing, and the possibility of capturing closely related compounds. At the same time, the bill’s supporters appear to have viewed those broad definitions as necessary to keep pace with rapidly changing illicit drug formulations and overdose risks.
HB417 amends Mississippi Code Section 41-29-113, expanding Schedule I to include five additional substances and reinforcing the state’s authority to regulate newly emerging synthetic drugs. The change affects criminal enforcement, prosecution, and regulatory treatment of the listed substances by making them Schedule I controlled substances under Mississippi law. It also leaves intact existing statutory exemptions for hemp and certain FDA-approved or industrial hemp-derived products, while continuing to define broad categories of fentanyl analogs, synthetic cannabinoids, synthetic cathinones, and related compounds.
The bill’s reception was overwhelmingly positive and bipartisan, with unanimous passage in both the House and Senate. The vote totals suggest broad agreement that the listed substances pose significant public-safety risks and should be controlled at the highest level. No committee testimony or recorded floor controversy is provided, so the available context indicates little to no opposition.
The main potential point of contention is the bill’s broad, chemistry-based scheduling approach, especially the inclusion of entire classes of fentanyl-related substances and synthetic cannabinoid/cathinone analogs. Critics of such language typically worry it may sweep in future compounds or closely related substances that have not yet been individually evaluated, while supporters argue that broad definitions are needed to stay ahead of illicit drug manufacturers. In the available record, however, no organized opposition or specific disputed amendment is shown.